Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 42.3% from a year ago
Total equity stood at $86.99M at the end of Q1 FY2026, down 42.3% from a year earlier and down 18.4% from the prior quarter.
Context
- Total equity amounted to 88.2% of total assets at the end of Q1 FY2026, down 7.7 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -42.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 106.63M USD
- Year-over-year change
- +295.1%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106.63M | +295.1% |
| FY2024 | 2024-12-31 | (54.64M) | -57.0% |
| FY2023 | 2023-12-31 | (34.8M) | -24.6% |
| FY2022 | 2022-12-31 | (27.92M) | — |
Total Equity vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total equity of $86.99M is the 8th highest of the 11 companies compared; the peer median is $111.39M.
- Its year-over-year change of -42.3% is the 8th highest of 11, against a peer median of -17.5%.
- Total equity amounts to 88.2% of total assets for AARD, versus a peer median of 73.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $216.9M | +43.3% | — | 94.9% |
| Mar 2026 | $198.61M | +632.0% | +35.7% | 84.3% | |
| Mar 2026 | $144.42M | -25.7% | -20.7% | 81.2% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $136.64M | +405.4% | +102.0% | 93.7% |
| Mar 2026 | $116.59M | +24.6% | -41.4% | 37.0% | |
| Mar 2026 | $106.19M | -11.1% | -20.3% | 78.6% | |
| Mar 2026 | $102.02M | -53.0% | -25.9% | 68.5% | |
| Mar 2026 | $86.99M | -42.3% | — | 88.2% | |
| Mar 2026 | $68.32M | -44.3% | — | 68.4% | |
| Mar 2026 | $31.27M | -69.7% | -30.8% | 48.6% | |
| Mar 2026 | -$76.41M | -23.9% | — | 34.4% | |
| Peer median (excluding AARD) | $111.39M | -17.5% | -20.7% | 73.5% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.